Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 2,405 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dysplasia Mild Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease

NCT02984540
View directory record Official record
Conditions
Mild Cognitive Impairment, Insulin Resistance
Interventions
Low-Carbohydrate Diet, Low-Fat Diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

NCT00422981
View directory record Official record
Conditions
Mild Cognitive Impairment, So Stated
Interventions
AL-108, Placebo
Drug
Lead sponsor
Allon Therapeutics
Industry
Eligibility
55 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
17
States / cities
Peoria, Arizona • Garden Grove, California • National City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

NCT07018492
View directory record Official record
Conditions
Hepatic Impairment
Interventions
BPN14770
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rural Veterans With Post-traumatic Stress Disorder (PTSD) And Comorbid Mild Traumatic Brain Injury (TBI): A Feasibility Study

NCT01278316
View directory record Official record
Conditions
Post-Traumatic Stress Disorders, Traumatic Brain Injury
Interventions
Control, Cognitive Training
Behavioral
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
20 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects

NCT02320045
View directory record Official record
Conditions
Renal Insufficiency
Interventions
ITCA 650 (Exenatide in osmotic mini pump)
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
25 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

NCT05882032
View directory record Official record
Conditions
Healthy, Hepatic Insufficiency
Interventions
LY3502970
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Use of Resveratrol to Decrease Acute Secondary Brain Injury Following Sports-Related Concussions in Boxers

NCT01321151
View directory record Official record
Conditions
Sports Concussion
Interventions
Resveratrol, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

NCT01230853
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Active Comparator: A, Placebo Comparator B, Active Comparator B, Placebo Comparator A
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658632
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
85
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 2 Interventional

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

NCT01602393
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 79 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 2 Interventional

Effects of Delivery Mode of Cognition Intervention in Early Alzheimer's Disease

NCT00611312
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Cognitive Training
Behavioral
Lead sponsor
University of Kansas
Other
Eligibility
60 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 2 Interventional

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

NCT03394677
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.5% ointment, Vehicle ointment
Drug
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Los Angeles, California • Oklahoma City, Oklahoma • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 24, 2026, 2:04 AM EDT
Recruiting Not applicable Interventional

External Therapy for Tinnitus Management

NCT07017998
View directory record Official record
Conditions
Tinnitus, Tinnitus, Subjective
Interventions
Cold pack-delivered mild therapeutic hypothermia, Sham (No Treatment)
Device
Lead sponsor
Restorear Devices LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 24, 2026, 2:04 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Development of a Neurocognitive Screening Test

NCT02597504
View directory record Official record
Conditions
Brain Concussion, Mild Cognitive Impairment
Interventions
Pen and paper neuropsychological test, Quick Test
Other · Device
Lead sponsor
ImPACT Applications, Inc.
Industry
Eligibility
6 Years to 75 Years
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
4
States / cities
Scottsdale, Arizona • Fayetteville, Arkansas • Crofton, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Not applicable Interventional Results available

Cranial Electrotherapy Stimulation (CES) Therapy

NCT02453347
View directory record Official record
Conditions
TBI, Anxiety, PTSD, Depression
Interventions
CES Therapy
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

NCT06916078
View directory record Official record
Conditions
Liver Dysfunction, Healthy
Interventions
Lepodisiran
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

NCT01532648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX®, Placebo, 5-ASA
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Anaheim, California • Lakewood, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 24, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract

NCT01331486
View directory record Official record
Conditions
Prehypertension, Mild Hypertension
Interventions
Hawthorn, Placebo capsule
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 24, 2026, 2:04 AM EDT
Terminated Not applicable Interventional Results available

Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse

NCT01648751
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Vaginal estrogen, Placebo
Drug
Lead sponsor
Pamela Moalli
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 2:04 AM EDT
Not listed Not applicable Interventional

TIME Study: Therapeutic Hypothermia for Infants With Mild Encephalopathy

NCT04176471
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy Mild, Neonatal Encephalopathy
Interventions
Therapeutic Hypothermia, Normothermia
Other
Lead sponsor
Stanford University
Other
Eligibility
Up to 6 Hours
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Loma Linda, California • Oakland, California • Orange, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 24, 2026, 2:04 AM EDT
Completed No phase listed Observational

Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses

NCT01898767
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 24, 2026, 2:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease

NCT04896606
View directory record Official record
Conditions
Covid19
Interventions
Standard of Care, SARS-CoV2-CTLS
Other · Biological
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Valhalla, New York • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 2:04 AM EDT
Not yet recruiting Phase 2 Interventional

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

NCT07808333
View directory record Official record
Conditions
Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions
Nicotinamide, Standard Glaucoma Therapy
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 24, 2026, 2:04 AM EDT
Recruiting Not applicable Interventional

Superior Parietal iTBS for PD-MCI

NCT07701785
View directory record Official record
Conditions
Parkinson Disease, Mild Cognitive Impairment
Interventions
Accelerated intermittent theta-burst stimulation (iTBS) rTMS to right superior parietal lobule (rSPL)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 24, 2026, 2:04 AM EDT